Launch of Novel Gene Therapy Company, VectorY, to Develop Innovative Vectorized Antibodies
Targeting muscular and neurodegenerative disorders
Amsterdam-based company seeded by Forbion
Co-founded by highly experienced gene therapy technology and manufacturing team
VectorY, a fully integrated gene therapy company focused on the development of innovative vectorized antibodies for muscular and neurodegenerative disorders, today announces its official launch. The Company has been operational since October 2020 and has established its laboratories and offices at the Amsterdam Science Park in The Netherlands.
VectorY develops proprietary and partnered programs based on a novel AAV platform and innovative antibody-based targeted degradation technologies. The Company is creating a pipeline of innovative vectorized antibodies targeting muscular and CNS diseases, aimed at overcoming limitations of current therapies, specifically by improving delivery, durability and accessibility of targe